Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
NEW YORK, Jan. 03, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ:ILMN) between July 26, 2016 and October 10, 2016. You are hereby notified that a securities class action has commenced in the USDC for the Southern District of California. To get more information go to:
http://www.zlk.com/pslra/illumina-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants failed to disclose that: (1) Illumina was suffering a large decline in its instrument sales; (2) this decline was damaging Illumina’s revenue; (3) Illumina lacked visibility into trends that could have a substantial impact on its financial results; (4) as such, Illumina’s revenue guidance was unreliable and overstated; and (5) consequently, Illumina’s statements concerning its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On October 10, 2016 Illumina announced disappointing financial results for the third quarter of fiscal year 2016. The company had predicted revenues of $625 to $630 million for the quarter. However, citing “declining demand for its high-speed genetic sequences” Illumina generated just $607 million. Following this news, Illumina stock dropped as much as 25% during intraday trading on October 11, 2016.
If you suffered a loss in Illumina you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
